Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis.

Article Details

Citation

Copy to clipboard

Serrano-Martin X, Payares G, Mendoza-Leon A

Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis.

Antimicrob Agents Chemother. 2006 Dec;50(12):4214-6. Epub 2006 Oct 2.

PubMed ID

17015627 [ View in PubMed

]

Abstract

Glibenclamide reduced the rate of lesion growth in BALB/c mice infected with Leishmania (Leishmania) mexicana, the effect was dose dependent, and the highest dose proved more effective than glucantime. Cross-resistance to glucantime was found in animals infected with a glibenclamide-resistant line, but combined therapy reduced lesion progression even in the glibenclamide-resistant strain.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Glyburide	Sulfonylurea receptor 1, Kir6.2 (Protein Group)	Protein group	Humans	Yes	Blocker	Details
Glymidine	ATP-sensitive inward rectifier potassium channel 1	Protein	Humans	Yes	Other/unknown	Details